Business Context and Reporting Period
This Form 8-K filing by Inogen, Inc. is dated August 17, 2015. The report addresses a significant change in the Company's independent registered public accounting firm and discloses a material weakness in internal controls over financial reporting.
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on governance and audit matters.
Material Changes
- Dismissal of Auditor: On August 17, 2015, the Audit Committee dismissed BDO USA, LLP as the independent registered public accounting firm, effective immediately.
- Engagement of New Auditor: Deloitte & Touche LLP was engaged as the new independent registered public accounting firm, effective August 19, 2015.
- Audit History: BDO's reports for fiscal years 2013 and 2014 were unqualified. There were no disagreements regarding accounting principles or practices prior to dismissal.
Management Commentary, Risks, and Contingencies
The filing discloses a material weakness in internal control over financial reporting as of December 31, 2014, and the quarters ended March 31, 2015, and June 30, 2015.
- Root Cause: The Company lacked adequately designed controls to review sales order documentation for direct-to-consumer sales and rentals prior to revenue recognition.
- Consequence: This deficiency prevented the detection of improper technology used to simulate medical documentation in 2014 and the first quarter of 2015.
- Risk: Management concluded there is a reasonable possibility that a material misstatement related to revenue recognition may occur and/or not be detected on a timely basis.
Investor Verification Checklist
- Verify the transition timeline and scope of work between BDO USA, LLP and Deloitte & Touche LLP.
- Review the Company's remediation plan for the material weakness regarding revenue recognition controls.
- Examine the extent of financial restatements required due to the improper use of technology to simulate medical documentation.
- Confirm the status of the letter from BDO USA, LLP (Exhibit 16.1) regarding their agreement with the Company's statements.